Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Awada

Showing results (191-200 of 210) with videos related to

Pageof 21
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutionsA F Ferreira Filho, A Di Leo, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2011
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapyA Hendlisz, V Golfinopoulos, C Garcia, et al.
British Journal of Cancer|March 23, 2013
Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patientsP El Hajj, F Journe, M Wiedig, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I studyO van Tellingen, C J Punt, A Awada, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II study of E7070 in patients with metastatic melanomaJ F Smyth, S Aamdal, A Awada, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancerA Awada, A Van Vreckem, R Paridaens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2002
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedulesA Awada, S Giacchetti, B Gerard, et al.
British Journal of Cancer|June 13, 2015
SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanomaP El Hajj, D Gilot, M Migault, et al.
Pageof 21

Showing results (191-200 of 210) with videos related to

Sort By:
Pageof 21
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutionsA F Ferreira Filho, A Di Leo, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2011
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapyA Hendlisz, V Golfinopoulos, C Garcia, et al.
British Journal of Cancer|March 23, 2013
Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patientsP El Hajj, F Journe, M Wiedig, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I studyO van Tellingen, C J Punt, A Awada, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II study of E7070 in patients with metastatic melanomaJ F Smyth, S Aamdal, A Awada, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancerA Awada, A Van Vreckem, R Paridaens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2002
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedulesA Awada, S Giacchetti, B Gerard, et al.
British Journal of Cancer|June 13, 2015
SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanomaP El Hajj, D Gilot, M Migault, et al.
Pageof 21